Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 14 studies | 26% ± 8% | |
oligodendrocyte | 12 studies | 33% ± 13% | |
microglial cell | 10 studies | 28% ± 10% | |
oligodendrocyte precursor cell | 10 studies | 37% ± 15% | |
macrophage | 9 studies | 26% ± 8% | |
astrocyte | 9 studies | 30% ± 11% | |
B cell | 7 studies | 18% ± 3% | |
fibroblast | 7 studies | 23% ± 4% | |
dendritic cell | 7 studies | 23% ± 9% | |
natural killer cell | 6 studies | 17% ± 1% | |
myeloid cell | 5 studies | 22% ± 3% | |
epithelial cell | 5 studies | 37% ± 10% | |
mast cell | 5 studies | 24% ± 5% | |
GABAergic neuron | 4 studies | 25% ± 4% | |
T cell | 4 studies | 20% ± 4% | |
CD4-positive, alpha-beta T cell | 4 studies | 17% ± 2% | |
ciliated cell | 4 studies | 26% ± 5% | |
lymphocyte | 4 studies | 27% ± 8% | |
glutamatergic neuron | 4 studies | 25% ± 6% | |
endothelial cell of lymphatic vessel | 4 studies | 20% ± 5% | |
regulatory T cell | 4 studies | 16% ± 1% | |
neuron | 4 studies | 38% ± 13% | |
hematopoietic precursor cell | 3 studies | 23% ± 2% | |
non-classical monocyte | 3 studies | 23% ± 9% | |
glial cell | 3 studies | 22% ± 5% | |
adipocyte | 3 studies | 26% ± 4% | |
effector memory CD8-positive, alpha-beta T cell | 3 studies | 18% ± 2% | |
abnormal cell | 3 studies | 26% ± 7% | |
connective tissue cell | 3 studies | 19% ± 4% | |
leukocyte | 3 studies | 29% ± 2% | |
alveolar macrophage | 3 studies | 27% ± 8% | |
monocyte | 3 studies | 24% ± 3% | |
smooth muscle cell | 3 studies | 18% ± 2% | |
basal cell | 3 studies | 26% ± 11% | |
goblet cell | 3 studies | 29% ± 18% | |
transit amplifying cell | 3 studies | 33% ± 19% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 2063.70 | 1445 / 1445 | 100% | 50.51 | 183 / 183 |
breast | 100% | 2513.02 | 459 / 459 | 100% | 41.82 | 1117 / 1118 |
lung | 100% | 2695.33 | 578 / 578 | 100% | 47.12 | 1153 / 1155 |
bladder | 100% | 2188.71 | 21 / 21 | 100% | 49.28 | 503 / 504 |
thymus | 100% | 2515.34 | 653 / 653 | 100% | 43.60 | 602 / 605 |
stomach | 99% | 1251.55 | 357 / 359 | 100% | 43.97 | 286 / 286 |
brain | 100% | 1376.98 | 2631 / 2642 | 100% | 41.06 | 704 / 705 |
uterus | 100% | 2499.56 | 170 / 170 | 99% | 52.10 | 456 / 459 |
intestine | 100% | 1744.11 | 966 / 966 | 99% | 46.47 | 523 / 527 |
ovary | 100% | 2384.64 | 180 / 180 | 99% | 29.87 | 426 / 430 |
kidney | 100% | 1769.43 | 89 / 89 | 99% | 31.58 | 891 / 901 |
prostate | 100% | 2262.38 | 245 / 245 | 98% | 28.94 | 494 / 502 |
skin | 100% | 2744.44 | 1809 / 1809 | 98% | 51.89 | 464 / 472 |
pancreas | 99% | 1215.94 | 325 / 328 | 99% | 48.03 | 176 / 178 |
adrenal gland | 100% | 1559.66 | 258 / 258 | 95% | 29.45 | 219 / 230 |
liver | 100% | 1077.18 | 226 / 226 | 78% | 14.02 | 318 / 406 |
adipose | 100% | 2561.73 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 2454.06 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 58.64 | 29 / 29 |
muscle | 100% | 2956.77 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 2652.24 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 41.85 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 20.15 | 1 / 1 |
heart | 99% | 1649.34 | 855 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 95% | 2343.20 | 879 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 80% | 14.61 | 64 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006366 | Biological process | transcription by RNA polymerase II |
GO_0060216 | Biological process | definitive hemopoiesis |
GO_0001649 | Biological process | osteoblast differentiation |
GO_0043371 | Biological process | negative regulation of CD4-positive, alpha-beta T cell differentiation |
GO_0030099 | Biological process | myeloid cell differentiation |
GO_0043378 | Biological process | positive regulation of CD8-positive, alpha-beta T cell differentiation |
GO_0000209 | Biological process | protein polyubiquitination |
GO_0048469 | Biological process | cell maturation |
GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
GO_0030098 | Biological process | lymphocyte differentiation |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
GO_0005654 | Cellular component | nucleoplasm |
GO_0016513 | Cellular component | core-binding factor complex |
GO_0016020 | Cellular component | membrane |
GO_0003713 | Molecular function | transcription coactivator activity |
GO_0005515 | Molecular function | protein binding |
GO_0043565 | Molecular function | sequence-specific DNA binding |
Gene name | CBFB |
Protein name | Core-binding factor subunit beta Core-binding factor subunit beta (CBF-beta) (Polyomavirus enhancer-binding protein 2 beta subunit) (PEA2-beta) (PEBP2-beta) (SL3-3 enhancer factor 1 subunit beta) (SL3/AKV core-binding factor beta subunit) |
Synonyms | |
Description | FUNCTION: Forms the heterodimeric complex core-binding factor (CBF) with RUNX family proteins (RUNX1, RUNX2, and RUNX3). RUNX members modulate the transcription of their target genes through recognizing the core consensus binding sequence 5'-TGTGGT-3', or very rarely, 5'-TGCGGT-3', within their regulatory regions via their runt domain, while CBFB is a non-DNA-binding regulatory subunit that allosterically enhances the sequence-specific DNA-binding capacity of RUNX. The heterodimers bind to the core site of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL3 and GM-CSF promoters. CBF complexes repress ZBTB7B transcription factor during cytotoxic (CD8+) T cell development. They bind to RUNX-binding sequence within the ZBTB7B locus acting as transcriptional silencer and allowing for cytotoxic T cell differentiation. . |
Accessions | H3BSC0 ENST00000290858.11 [Q13951-1] ENST00000561924.6 ENST00000565389.1 ENST00000563939.3 A0A494C0A9 Q13951 ENST00000650873.1 J3KRT0 ENST00000412916.7 [Q13951-2] ENST00000564034.6 J3KTD8 J3KS23 |